BUIR logo
Communities & Collections
All of BUIR
  • English
  • Türkçe
Log In
Please note that log in via username/password is only available to Repository staff.
Have you forgotten your password?
  1. Home
  2. Browse by Subject

Browsing by Subject "Liver cirrhosis"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    ItemOpen Access
    PPAR-alpha L162V polymorphism in human hepatocellular carcinoma
    (Turkish Society of Gastroenterology, 2008) Koytak, E. S.; Mızrak, D.; Bektaş, M.; Verdi, H.; Arslan-Ergül, Ayça; İdilman, R.; Çınar, K.; Yurdaydın, C.; Ersöz, S.; Karayalçın, K.; Uzunalimoğlu, Ö.; Bozkaya, H.
    Background/aims: Several lines of evidence suggest that peroxisome proliferator-activated receptor alpha may be involved in hepatocarcinogenesis. L162V polymorphism of the peroxisome proliferator-activated receptor alpha gene enhances the transactivation activity of this transcription factor. The aim of this study was to determine the frequency and clinical correlates of peroxisome proliferator-activated receptor alpha L162V polymorphism in hepatitis virus-induced hepatocellular carcinoma. Methods: 90 hepatocellular carcinoma patients diagnosed at Ankara University Gastroenterology Clinic between January 2002 and July 2003 and 80 healthy controls with normal body mass index, blood chemistry and with negative viral serology were included. peroxisome proliferator-activated receptor alpha L162V polymorphism was determined by PCR-RFLP. Results: hepatocellular carcinoma etiologies were as follows: 56 HBV, 12 HBV+HDV, 22 HCV. Eighty-seven patients (97%) were cirrhotic, and 60 patients (67.5%) had advanced tumors. In 83 (92%) of 90 hepatocellular carcinoma patients, gene segment including polymorphic region could be amplified by PCR (50 HBV, 12 HBV+HDV, 21 HCV) and 6 of them (7.2%, all infected with HBV) had L162V polymorphism, while 2 (2.5%) of 80 controls had this polymorphism (p=0.162). This trend became more remarkable when only HBV (HBV+HDV)-infected patients were compared with controls (6/62, 9.7% vs. 2/80, 2.5%, respectively, p=0.071). Five of 6 patients with L162V had advanced disease. Conclusions: Peroxisome proliferator-activated receptor alpha L162V polymorphism tends to occur in HBV-induced epatocellular carcinoma and is absent in HCV-related epatocellular carcinoma. These findings may show clues for the existence of different carcinogenesis mechanisms in these two common etiologies. Frequent occurrence of advanced disease in patients with L162V polymorphism suggests a role for this polymorphism in tumor progression.

About the University

  • Academics
  • Research
  • Library
  • Students
  • Stars
  • Moodle
  • WebMail

Using the Library

  • Collections overview
  • Borrow, renew, return
  • Connect from off campus
  • Interlibrary loan
  • Hours
  • Plan
  • Intranet (Staff Only)

Research Tools

  • EndNote
  • Grammarly
  • iThenticate
  • Mango Languages
  • Mendeley
  • Turnitin
  • Show more ..

Contact

  • Bilkent University
  • Main Campus Library
  • Phone: +90(312) 290-1298
  • Email: dspace@bilkent.edu.tr

Bilkent University Library © 2015-2025 BUIR

  • Privacy policy
  • Send Feedback